Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 56, Issue 4, 2001, Pages 293-300

  Gabrielsson, S ^a   Söderlund, Ankie ^a   Paulie, S ^a   Van Der Pouw Kraan, T C T M ^b   Troye Blomberg, M ^a   Rak, S ^c  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b CENTRAL LABORATORY   (Netherlands)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allergen specific; Atopy; IL 13; IL 4; Immunotherapy

Indexed keywords

ALUTARD; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ADULT; ARTICLE; ATOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; POLLEN; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION;

ADULT; ANTIBODY-PRODUCING CELLS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; MALE; MIDDLE AGED; POLLEN; SEASONS;

EID: 0035103336     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2001.00472.x     Document Type: Article

References (48)

1. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
2. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: A double-blind study
3. Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response
4. Allergen-controlled study of intranasal immunotherapy for ragweed hay fever
5. Nasal immunotherapy in weed-induced allergic rhinitis
6. Immunotherapy in atopic allergy - Antibody titres and avidities during hyposensitization with birch and timothy pollen allergens
7. Analysis of house dust mite-specific IgE, IgG4, and IgG antibodies during immunotherapy in asthmatic children
8. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy
9. Immunologic changes associated with allergen immunotherapy
10. Monitoring allergen immunotherapy of pollen-allergic patients: The ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome
11. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
12. Grass immunotherapy induces inhibition of allergen-specific human peripheral blood mononuclear cell proliferation
13. + T cells from allergic individuals
14. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects
15. Study on changes in the level of serum IL-4 and soluble CD23 (s-CD23) with immunotherapy in nasal allergy patients
16. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
17. Increases in IL-12 messenger RNA + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy
18. Immunotherapy affects the seasonal increase in specific IgE and interleukin-4 in serum of patients with seasonal allergic rhinitis
19. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of the Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis
20. Expression of lymphocytes FcεRII/CD23 in allergic children undergoing hyposensitisation
21. Decrease in CD23 + B lymphocytes and clinical outcome in asthmatic patients receiving specific rush immunotherapy
22. Increased frequencies of allergen-induced interleukin-13-producing cells in atopic individuals during the pollen season
23. Human IL-13 production is negatively influenced by CD3 engagement - Enhancement of IL-13 production by cyclosporin A
24. Specific induction of interleukin-4-producing cells in response to in vitro allergen stimulation in atopic individuals
25. Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation
26. The influence of cryopreservation on cytokine production by human T lymphocytes
27. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells
28. Differential spontaneous expression of mRNA for IL-4, IL-10, IL-13, IL-2 and interferon-gamma (IFN-γ) in peripheral blood mononuclear cells (PBMC) from atopic patients
29. Role of IL-13 in CD4 T cell-dependent IgE production in atopy
30. IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-γ expression
31. Clonal diversity of IL-4 and IL-13 expression in human allergen-specific T lymphocytes
32. IL-13 expression at the sites of allergen challenge in patients with asthma
33. Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitics
34. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen
35. Decrease of allergen-specific T-cell response induced by local nasal immunotherapy
36. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γ and IL-4 expression by circulating T lymphocytes
37. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes
38. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: Comparison of rush and conventional immunotherapy
39. 2-derived peptides by conventional bee venom immunotherapy
40. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4
41. IgE versus IgG4 production can be differently regulated by IL-10
42. Role of interleukin 10 in specific immunotherapy
43. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production
44. Differential effects of interleukin-4 and -10 on interleukin-2 induced interferon-γ synthesis and lymphokine activated killer activity
45. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
46. IgG subclass restricted immune responses to allergens
47. Serologic aspects of IgG4 antibodies. I. Prolonged immunisation results in an IgG4-restricted response
48. Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients